Back to Single Peptide Protocols
Single PeptideGrowth Hormone & Performance5 mg vial2–3× dailySubcutaneousGHRH
CJC-1295 (No DAC) (5 mg Vial) Dosage Protocol
CJC-1295 (No DAC) dosage protocol for the 5 mg vial. GHRH analogue with short half-life for pulsatile GH release.
Vial Size
5 mg
Route
Subcutaneous
Frequency
2–3× daily (pulsatile)
Dose Range
100–200 mcg per injection
Dosage Schedule
| Period | Dose |
|---|---|
| Weeks 1–2 (starter) | 100 mcg per injection |
| Weeks 3+ (maintenance) | 100–200 mcg per injection |
Route: Subcutaneous · Frequency: 2–3× daily (pulsatile) · Cycle: 8–12 weeks
How It Works
CJC-1295 (No DAC) is a modified GHRH analogue with a short half-life (~30 minutes), producing pulsatile GH release that mimics natural physiology. Often stacked with Ipamorelin for synergistic GH stimulation.
Potential Benefits
- •Pulsatile GH release mimicking natural physiology.
- •Synergistic when stacked with Ipamorelin.
- •Supports lean body composition and recovery.
Side Effects & Risks
- •Mild water retention.
- •Transient headache or flushing.
- •Prohibited by WADA.
Important Notes
- Administer on an empty stomach for optimal effect.
- Commonly stacked with Ipamorelin (see blend protocol).
Storage Instructions
- Lyophilized: −20 °C (−4 °F).
- Once mixed: 2–8 °C; use within 14–21 days.
References
- [1]Ionescu M, Frohman LA. Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295. J Clin Endocrinol Metab 2006.View Source
Research & Educational Use Only: This protocol is for educational and research purposes only. It does not constitute medical advice, diagnosis, or treatment. Always consult a qualified healthcare professional before making any decisions related to peptides or any other compounds.